BRIC Countries (Brazil, Russia, India, China) Generics Market Summary, Competitive Analysis and Forecast to 2027


Summary

The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.


Key Highlights

  • Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $144,339.7 million in 2022. China was the fastest growing country with a CAGR of 14.1% over the 2018-22 period.
  • Within the generics industry, China is the leading country among the BRIC nations with market revenues of $111,666.9 million in 2022. This was followed by India, Russia and Brazil with a value of $17,617.5, $11,917.6, and $3,137.6 million, respectively.
  • China is expected to lead the generics industry in the BRIC nations with a value of $171,144.4 million in 2027, followed by India, Russia, Brazil with expected values of $26,308.6, $18,326.1 and $4,730.2 million, respectively.




Scope

  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC generics market
  • Leading company profiles reveal details of key generics market players’ BRIC operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the BRIC generics market with five year forecasts by both value and volume
  • Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country




Reasons To Buy

  • What was the size of the BRIC generics market by value in 2022?
  • What will be the size of the BRIC generics market in 2027?
  • What factors are affecting the strength of competition in the BRIC generics market?
  • How has the market performed over the last five years?
  • How large is the BRIC generics market in relation to its regional counterparts?